Published in Hepatitis Weekly, August 25th, 2003
According to recent research published in the journal Hepatology, "it has been suggested that hepatitis C virus (HCV) and especially genotype 3 is associated with steatosis. We assessed the effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis. We analyzed 1,428 naive patients included in a randomized trial."
"A single pathologist scored steatosis at baseline and 24 weeks after the treatment. At baseline, steatosis was present in 935 of 1428 patients (65%), including 175 (83%) of 210 patients with genotype 3 versus 760 (62%) of 1218 with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.